SuperworthTalphera EPS TLPH
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Mar 31, 2025
- n/m
- a quarter missing
- Latest quarter, Q1 FY25
- −$0.10
- Fiscal year 2023
- −$1.48
- −127% on the year before
Talphera's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q1 FY25, it was −$0.10.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2023 | −$1.48 | −127% |
| FY2022 | $5.55 | n/a |
| FY2021 | −$5.84 | n/a |
| FY2020 | −$9.60 | n/a |
| FY2019 | −$13.40 | n/a |
| FY2018 | −$16.40 | n/a |
| FY2017 | −$22.20 | n/a |
| FY2016 | −$19.00 | n/a |
| FY2015 | −$12.00 | n/a |
| FY2014 | −$19.40 | n/a |
| FY2013 | −$13.20 | n/a |
| FY2012 | −$30.00 | n/a |
| FY2011 | −$23.60 | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY25 | −$0.10 | n/a | n/a | |
| Q1 FY24 | −$0.16 | n/a | −$0.89 | |
| Q4 FY23 | −$0.25 | n/a | −$1.48 | |
| Q3 FY23 | −$0.08 | n/a | −$2.13 | |
| Q2 FY23 | −$0.40 | −105% | −$2.99 | |
| Q1 FY23 | −$0.75 | n/a | $5.99 | |
| Q4 FY22 | −$0.90 | n/a | $5.55 | |
| Q3 FY22 | −$0.94 | n/a | $5.21 | |
| Q2 FY22 | $8.58 | n/a | $4.75 | |
| Q1 FY22 | −$1.19 | n/a | −$5.43 | |
| Q4 FY21 | −$1.24 | n/a | −$5.84 | |
| Q3 FY21 | −$1.40 | n/a | −$6.60 |
Against its peers
Companies in Drug Manufacturers - General nearest Talphera's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TLPHTalphera | n/m | |
| SPROSpero Therapeutics | $0.11 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Talphera
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.